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Background: The expression status of bone morphogenetic protein 4 (BMP4) in gliomas is still unclear by now. We
try to investigate the relationship between BMP4 expression and the biological behavior of gliomas in order to lay
a foundation for the management of these tumors.
Methods: A total of 630 patients with glioma were enrolled in the study from January 2002 to January 2008. The
expression status of BMP4 in gliomas was evaluated by RT-PCR and immunohistochemistry. The relationships
between BMP4 expression and clinicopathological parameters and between BMP4 expression and prognosis were
also studied.
Results: The expression of BMP4 in tumor tissues was significantly lower than that in the paracancer tissues at both
mRNA and protein levels (P = 0.01 and 0.001, respectively). Univariate analysis showed that BMP4 expression was
closely related to extent of resection, Ki-67 expression, and the WHO grade (P = 0.001, 0.001, and 0.001,
respectively), but it was not related to age, sex, or the Karnofsky Performance Status (KPS) score (P = 0.099, 0.472,
and 0.201, respectively). Finally, Ki-67 expression and the WHO grade were found to be related to BMP4 expression
using logistic regression (P = 0.001 and 0.001, respectively). Interestingly, we found that the expression of BMP4 was
significantly related to distant glioma metastasis. Cox regression analysis identified the KPS score, extent of
resection, Ki-67 expression, WHO grade, and BMP4 expression as independent prognostic factors (P = 0.044, 0.010,
0.002, 0.001, and 0.001, respectively).
Conclusions: BMP4 is differentially expressed in glioma patients and is closely related to the biological behavior of
gliomas. BMP4 expression was found to be a strong predictor of distant metastasis and postoperative prognosis.
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A glioma is a type of tumor that starts in the brain or
spine. Gliomas make up approximately 30% of all brain
and central nervous system tumors and 80% of all
malignant brain tumors [1]. They are fast growing and
have a high recurrence rate [2]. The five-year survival
rate for patients with glioma is low even with surgery,
radiotherapy, chemotherapy, and other forms of treat-
ment [3]. Because of the infiltrative growth of gliomas,
it is difficult to resect the whole tumor without causing
serious damage to brain function [4]. The use of mo-
lecular biology methods to explore the pathogenic basis
of gliomas may yield further insight into the treatment
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reproduction in any medium, provided the orBone morphogenetic proteins (BMPs) are multifunc-
tional growth factors that belong to the transforming
growth factor beta (TGF-β) superfamily [5]. Members of
the TGF-β superfamily are synthesized as precursor mac-
romolecules, and the mature protein is released from the
propeptide by proteolytic cleavage [6]. BMPs have been
grouped into 15 categories, which are divided into three
subsets according to amino acid sequence: BMP2 and
BMP4, BMP5 and BMP8, and BMP3 and GDF10. BMP4
expression is closely related to the grade of malignancy in
gastric carcinoma [7].
A characteristic of brain gliomas is the presence of
stem-like cells in the tumor tissue that can develop into
any kind of cell when stimulated by the correct ‘signal’ [8].
A recent study found that BMP4 can cause these neural
stem-cell-like clusters to lose their brood cell characteris-
tics, thereby terminating their ability to differentiate [9].
All mice infected with untreated glioma cells died afterLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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BMP4-treated cells survived.
At present, the expression status of BMP4 in gliomas
and the mechanism of BMP4 action are unclear, and
studies investigating the function and mechanism of this
molecule in the biological behavior of gliomas are still
rare. We studied the relationship between BMP4 expres-
sion and the biological behavior of gliomas in order to
provide a theoretical basis for the treatment of glioma.
Methods
Clinical specimens and experimental materials
Paraffin-embedded specimens of brain gliomas from 630
patients were collected at Liaoning Provincial Tumor Hos-
pital and Xinxiang Central Hospital from January 2002 to
January 2008. These cases were used for testing of protein
levels by immunohistochemistry and for analysis of patient
prognosis. The average age of enrolled patients was 46.33 ±
8.49 years (range from 34 to 77 years). Gliomas can be
divided into low-grade (World Health Organization
(WHO) grade II) and high-grade gliomas (WHO grade
III-IV) depending on their rate of growth [10]. Based on
histopathological examination, patients were divided into
two groups: 247 with low-grade gliomas and 383 with
high-grade gliomas. All patients were assessed by the
Karnofsky Performance Status (KPS) scale: (1) minor dis-
ability (80 to 100 points); (2) moderate disability (60 to 70
points); and (3) severe disability (10 to 50 points) [11].
The inclusion criteria were as follows: (a) resected speci-
mens underwent pathological examination, (b) enrolled
cases were successfully followed up, and (c) a complete
medical record was available. The study protocol was
approved by the Ethics Committee of Xinxiang Central
Hospital and written informed consent was obtained
from patients in the study.
RT-PCR
Total RNA was isolated using TRIzol Reagent (Life
Technologies, Carlsbad, CA, USA) according to the manu-
facturer’s instructions. cDNAs were synthesized using a
RevertAid First Strand cDNA Synthesis Kit (Fermentas,
Vilnius, Lithuania). Quantitative real-time PCR was per-
formed using SYBR Green PCR Master Mix on an Applied
Biosystems (Foster City, CA, USA) 7500 Fast Real-Time
PCR System. Primers used in the real-time PCR were as
follows: forward 5′-AGCAGCCAAACTATGGGCTA-3′
and reverse 5′-TGGTTGAGTTGAGGTGGTCA-3′. The
reaction conditions were 95°C for 5 min followed by 40 cy-
cles of 94°C for 15 s, and 55.5 or 55.2°C for 20 s. Melting
temperature curve analyses were performed after PCR.
Western blot
Protein concentrations were determined by bicinchoninic
acid (BCA) assay (Santa Cruz Biotechnology, Santa Cruz,CA, USA). Equal amounts of total protein were loaded
and separated by SDS-PAGE and transferred onto
polyvinylidene fluoride(PVDF) membranes. Membranes
were blocked using 5% fat-free milk in phosphate-
buffered saline (PBS) at 37°C for 2 h, followed by two
washes with phosphate-buffered saline/Tween (PBST).
Blots were then incubated with primary antibodies
to BMP4 (1:500; Cell Signaling Technology, Beverly,
MA, USA) or glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (1:800; Santa Cruz Biotechnology) at 4°C
overnight and washed four times with PBST before
adding secondary antibody (horseradish peroxidase
(HRP)-conjugated anti-rabbit or anti-mouse or anti-
goat immunoglobulin (Ig)G). Blots were incubated with
secondary antibody for 1 h at room temperature and
then washed four times with PBST. Protein bands were
visualized by chemiluminescence and the target protein
quantity was determined by normalizing the densities of
corresponding bands to those of the loading control
bands (GAPDH).
Immunohistochemistry
Tumor tissue microarray blocks were freshly cut into
4-μm thick sections. Sections were fixed on slides and
dried for 12 to 24 h at 37°C. Sections were subsequently
deparaffinized in xylene and rehydrated through a graded
series of ethanol to distilled water. After antigen retrieval,
sections were incubated for 60 min with primary antibody
to Ki-67 (sc-15402; Santa Cruz Biotechnology) or
BMP4 (1:500; Cell Signaling Technology). Following
washing with PBS, sections were incubated for 30 min
with the biotinylated secondary antibody (multi-link
swine anti-goat/mouse/rabbit immunoglobulin; Dako,
Glostrup, Denmark). After washing, Avidin/Biotin Com-
plex (1:1000; Vector Laboratories, Burlingame, CA, USA)
was applied to the sections for 30 to 60 min at room
temperature. The sections were washed and the immuno-
reactive products were visualized by oxidation of 3,3′-
diaminobenzidine (DAB) by HRP in the presence of H2O2.
Sections were then counter stained in Gill’s hematoxylin
and dehydrated in ascending grades of methanol before
clearing in xylene and mounting under a coverslip.
For negative controls, the primary antibody was
replaced by 0.01 mol/L PBS, and for positive controls,
normal breast tissue sections were used. Cells positive
for BMP4 were defined as those with brown granules in
the cytoplasm. Two hundred cells from two representative
fields of each section were counted by two independent
observers to determine the immunostaining intensity.
Staining intensity was recorded on a 4-point scale: 0,
no staining; 1, light brown (weak immunostaining); 2,
brown (moderate immunostaining); 3, dark brown
(strong immunostaining). Also, the extent of staining
was assessed on a 3-point scale: 0, <9% positive cells; 1,
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from the two scales were combined and each section was
classified as low/no BMP4 expression (0 to2) or high
BMP4 expression [3-6]. Ki-67 expression was classified
semi-quantitatively according to the following criteria:
samples were considered positive for Ki-67 if more than
10% of neoplastic cells discretely expressed Ki-67 in their
nucleus.Figure 2 Western blot analysis showed that BMP4 protein was
upregulated in paracancer tissues (No. 1, 2) compared with
glioma tissues and in low-grade glioma tissues (No. 3, 4)
compared with high-grade glioma tissues (No. 5, 6) (P = 0.001).Statistical analysis
All data were analyzed with SPSS Statistics software
(version 13.0; SPSS, Inc., Chicago, IL, USA). The rela-
tionships between BMP4 and other parameters were
studied using the chi-square test, Fisher’s exact test, or
independent t tests. Disease-specific survival was ana-
lyzed using the Kaplan-Meier method. The log-rank
test was used to analyze differences in survival. Multi-
variate analysis was performed using the Cox propor-
tional hazards model with forward stepwise selection.
A P value of less than 0.05 was considered statistically
significant.Results
BMP4 expression in human glioma tissues at mRNA and
protein levels
RT-PCR analysis of high-grade (WHO III-IV) and low-
grade (WHO I-II) tumor tissues showed that BMP4
mRNA expression was significantly lower in tumor
tissues than in paracancer tissues (Figure 1). Further-
more, BMP4 mRNA was upregulated in low-grade gli-
oma tissues when compared with high-grade glioma
tissues (P = 0.01) (Figure 1). Furthermore, in western
blot analysis, the BMP4 protein was upregulated in
low-grade glioma tissues when compared with high-
grade glioma tissues (P = 0.001). Moreover, BMP4 pro-
tein expression in tumor tissues was significantly lower
than that inparacancer tissues (P = 0.001) (Figure 2).Figure 1 RT-PCR analysis showed that BMP4 mRNA was
upregulated in paracancer tissues compared with low-grade or
high-grade glioma tissues (P = 0.01).Expression of BMP4 ingliomas and the relationship
between BMP4 expression and clinicopathological
characteristics
Immunohistochemical analyses showed that BMP4
localized in the cytoplasm of glioma cells (Figure 3).
BMP4 expression was observed in 36.98% (233/630) of
the glioma sections. Univariate analysis showed that
BMP4 expression was closely related to the extent of re-
section, Ki-67 expression, and the WHO grade (P = 0.001,
0.001, and 0.001, respectively), but it was not related to
patient age, gender, or KPS score (P = 0.099, 0.472, and
0.201, respectively) (Table 1). Finally, Ki-67 expression
and the WHO grade were found to be related to BMP4
expression using logistic regression (P = 0.001 and 0.001,
respectively) (Table 2).
Prognostic analysis
Survival analysis showed that patients with high BMP4
expression had significantly poorer postoperative disease-
specific survival than those with low/no BMP4 expression
(P = 0.001) (Figure 4). Cox regression analysis identified
the KPS score, extent of resection, Ki-67 expression,
WHO grade, and BMP4 expression as independent prog-
nostic factors (P = 0.044, 0.010, 0.002, 0.001, and 0.001,
respectively).
Discussion
BMP4 plays an important role in the development of the
nervous system [12]. It can induce neural stem cells to
differentiate into either neurons or astrocytes and may
affect neural stem cell differentiation through multiple
mechanisms. Although the basic function of BMP4 is to
induce bone formation, it is reported to play a role in
the development and metastasis of malignant tumors
[13]. BMP4 expression has been reported in osteosar-
coma, bone fibrous dysplasia, gastric cancer, prostate
cancer, and salivary gland tumors, and the expression of
this protein may affect the biological behavior of tumors
and the disease prognosis [14-16]. Gajera et al. [17]
reported that the biological behavior of osteosarcoma
cells with high BMP4 expression was obviously different
Figure 3 Expression of BMP4 in glioma tissues (×400). (A) Low-grade glioma stained for BMP4; (B) high-grade gliomas stained for BMP4.
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In another study, BMP4 also showed the two sides of
oncogenes and anti-oncogenes in breast cancer [19].
Kallioniemi et al. [20] reported that BMP4 could inhibit
the growth of breast cancer cells but could also induce
these cells to migrate, invade, and undergo epithelial to
mesenchymal transformation both in vivo and in vitro
[20]. Montesano et al. [21] reported that at concentra-
tions of 1 to 10 ng/mL, BMP4 could inhibit lumen
formation by epithelial cells in vitro, while at higher
concentrations (20 to 100 ng/mL) it could disrupt cell-Table 1 Relationship between BMP4 expression and
clinic-pathological factors of 630 gliomas
Variable n BMP4 (n(%)) X2 P value
+ -
Sex 0.517 0.472
Male 347 124(35.73) 223(64.27%)
Female 283 109(38.52) 174(61.48)
Age (years) 2.982 0.099
≤35 307 124(40.39) 183(59.61)
>35 323 109(33.75) 214(66.25)
KPS score 3.208 0.201
10-50 83 38(45.78) 45(54.22)
60-70 135 49(36.30) 86(63.70)
80-100 412 146(35.44) 266(64.56)
Extent of resection 21.702 0.001
Partial 139 28(20.14) 111(79.86)
Total 491 205(41.75) 286(58.25)
Ki67 78.795 0.001
+ 291 54(18.56) 237(81.44)
_ 339 179(52.80) 160(47.20)
WHO grade 40.996 0.001
II 247 128(51.82) 119(48.18)
III-IV 383 105(27.42) 278(72.58)
+, high BMP4 expression; –, loss/low BMP4 expression. KPS, Karnofsky
Performance Status; WHO, World Health Organization.cell adhesion, resulting in disorganization of the epithelial
cysts and the spreading of individual cells to the surround-
ing collagenous matrix [21].
In the nervous system, BMP4 plays a role in maintaining
and regulating the health and regeneration of peripheral
nerves. It acts as aneurotrophic factor that may be in-
volved in the occurrence and development of tumors of
the nervous system. A heterogeneity in BMP4 expression
depending on disease type, from benign disease to
malignant tumors [6,17-19], has been observed. BMP4
may also play different roles during different tumor
stages, but its mechanism in both benign and malig-
nant tumors of the nervous system [20,21] requires
further study.
Glioma prognosis is often poor, even when patients
undergo surgery combined with radiotherapy and chemo-
therapy. Research priorities over the next 10 years will
be focused on both basic and translational approaches.
New treatment methods may include new drugs that
block cell proliferation-inducing signaling pathways to
overcome resistance to chemotherapy. In some studies,
BMP4 has been observed to promote the differentiation
of glioma stem cells, inhibit their proliferation, and de-
crease tumorigenicity [6,9]. It may rely on signal trans-
ducer and activator of transcription(STAT) signaling. In
this function, BMP4 is the most potent member of theTable 2 Multivariate analysis of the factors related to
BMP4 expression
Characteristic Hazard ratio 95% CI P value
Sex 1.147 0.683-1.925 0.604
Age 0.998 0.624-1.597 0.998
KPS 1.140 0.843-1.541 0.396
Extent of resection 0.581 0.369-2.728 0.182
Ki67 1.605 1.241-2.076 0.001
WHO grade 3.901 1.705-8.928 0.001
Constant 1.704
CI, confidence interval; KPS, Karnofsky Performance Status; WHO, World Health
Organization.
Figure 4 Survival analysis of prognostic factors of glioma. KPS score (A), extent of resection (B), Ki-67 expression (C), WHO grade (D), and
BMP4 expression (E) as independent prognostic factors (P = 0.02, 0.001, 0.001, 0.001, and 0.001, respectively).
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inhibit growth of glioma cells [9].
A recent study found that BMP4 can cause neural
stem-cell-like clusters to lose their brood cell charac-
teristics, which interferes with their ability to divide.
Cells treated with BMP4 did not produce tumors in
infected mice, whereas mice infected with untreated
cells died [6]. But in clinical cases, the effect of BMP4expression on the prognosis for glioma is still unclear.
We found that the expression of BMP4 in low-grade
gliomas was significantly higher than that in high-
grade gliomas. BMP4 expression was closely related to
Ki-67 expression and WHO grade but was not corre-
lated with age, sex, KPS score, or extent of resection.
Interestingly, we found that high BMP4 expression
can increase bone metastasis from brain glioma. We
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factor for glioma.
Conclusion
Differential expression of BMP4 is closely related to the
biological behavior of brain gliomas. It is an independent
prognostic factor for glioma that can provide a basis for
clinical treatment of brain glioma.
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